LAVAL, QC, Aug. 17 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
commented on the outcome of patent-infringement litigation initiated by Purdue
Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to
Ultram(R) ER (tramadol hydrochloride extended-release tablets). The
patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc.,
the marketer of Ultram(R) ER. In his decision, Circuit Judge Kent Jordan
entered judgment in favor of Purdue and against Par on the issue of
infringement and rejected Par's claim that the patents were unenforceable for
inequitable conduct. Judge Jordan, however, entered judgment in favor of Par
and against Purdue on the issue of validity, citing obviousness.
This judgment could permit Par to market its generic formulation of
Ultram ER in the U.S., should it receive final regulatory approval from the
U.S. Food and Drug Administration. Although Labopharm is not a party to this
action, if Par was to launch its generic formulation of Ultram ER, it could
impact U.S. sales of Labopharm's own once-daily tramadol product, Ryzolt(TM),
which is marketed in the U.S. by Purdue. Ultram ER, and therefore any generic
version of it, is not A/B rated to Ryzolt, meaning it cannot be substituted
for Ryzolt at the pharmacy.
Labopharm is currently in discussions with Purdue to evaluate next steps
in this matter, including a potential appeal of the decision.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
now available in 17 countries around the world, including the U.S., Canada,
major European markets and Australia. The Company's second product, a novel
formulation of trazodone for the treatment of major depressive disorder, is
under regulatory review in the U.S. by the FDA. The Company also has a robust
pipeline of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become an integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
Ryzolt(TM) is a trademark of Purdue Pharma Products L.P.
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process in various
countries for the approval of the Company's products and the successful
commercialization of the products throughout the world if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm: Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group: Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
email@example.com; French: Joe Racanelli, Tel: (514) 844-7997,